Trevi Therapeutics Inc (NASDAQ: TRVI) is -8.74% lower on its value in year-to-date trading and has touched a low of $1.27 and a high of $4.68 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TRVI stock was last observed hovering at around $3.78 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $3.76, the stock is -7.82% and 9.48% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.26 million and changing -0.53% at the moment leaves the stock 23.69% off its SMA200. TRVI registered 178.52% gain for a year compared to 6-month gain of 41.35%. The firm has a 50-day simple moving average (SMA 50) of $3.4344 and a 200-day simple moving average (SMA200) of $3.039975.
The stock witnessed a -11.32% loss in the last 1 month and extending the period to 3 months gives it a 17.50%, and is -1.57% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.62% over the week and 7.86% over the month.
Trevi Therapeutics Inc (TRVI) has around 25 employees, a market worth around $336.02M and $0.00M in sales. Distance from 52-week low is 196.06% and -19.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-74.13%).
The EPS is expected to shrink by -66.76% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Trevi Therapeutics Inc (TRVI) Top Institutional Holders
120.0 institutions hold shares in Trevi Therapeutics Inc (TRVI), with institutional investors hold 71.21% of the company’s shares. The shares outstanding are 75.45M, and float is at 58.06M with Short Float at 6.66%. Institutions hold 70.47% of the Float.
The top institutional shareholder in the company is NEA MANAGEMENT COMPANY, LLC with over 11.37 million shares valued at $33.88 million. The investor’s holdings represent 11.4255% of the TRVI Shares outstanding. As of 2024-06-30, the second largest holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with 7.38 million shares valued at $22.0 million to account for 7.4169 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 5.03 million shares representing 5.0513% and valued at over $14.98 million, while VIKING GLOBAL INVESTORS LP holds 4.4213 of the shares totaling 4.4 million with a market value of $13.11 million.
Trevi Therapeutics Inc (TRVI) Insider Activity
The most recent transaction is an insider sale by GOOD JENNIFER L, the company’s President & CEO. SEC filings show that GOOD JENNIFER L sold 4,219 shares of the company’s common stock on Sep 06 ’24 at a price of $3.03 per share for a total of $12784.0. Following the sale, the insider now owns 0.21 million shares.
Trevi Therapeutics Inc disclosed in a document filed with the SEC on Sep 09 ’24 that GOOD JENNIFER L (President & CEO) sold a total of 1,840 shares of the company’s common stock. The trade occurred on Sep 09 ’24 and was made at $3.04 per share for $5587.0. Following the transaction, the insider now directly holds 0.21 million shares of the TRVI stock.
Still, SEC filings show that on Sep 05 ’24, GOOD JENNIFER L (President & CEO) disposed off 40,277 shares at an average price of $3.11 for $0.13 million. The insider now directly holds 213,313 shares of Trevi Therapeutics Inc (TRVI).
